Welcome to our dedicated page for Dariohealth SEC filings (Ticker: DRIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DarioHealth Corp. (NASDAQ: DRIO) SEC filings page on Stock Titan brings together the company’s regulatory disclosures made under the Securities Exchange Act of 1934, including Form 8-K current reports and other key documents. These filings provide detailed information on DarioHealth’s capital structure, financing transactions, governance decisions and material agreements, complementing its profile as a digital health company offering a multi-chronic condition digital therapeutics platform for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Recent Form 8-K filings describe several significant corporate actions. One filing outlines a twenty-for-one reverse stock split of DarioHealth’s common stock, including the effective date, treatment of fractional shares and the impact on outstanding shares and equity-linked instruments. Other 8-Ks report private placements of common stock and pre-funded warrants, including purchase agreements, pricing, exemptions from registration and commitments to file registration statements for resale of the securities.
DarioHealth’s SEC reports also detail amendments to certificates of designation for various series of preferred stock, accelerating mandatory conversion of these preferred shares into common stock or, at holders’ election, pre-funded warrants. Additional filings describe an amendment to the company’s credit agreement, including resets of financial covenants, liquidity requirements, reporting obligations and warrant amendments associated with the loan facility. These documents help investors understand how DarioHealth manages its debt obligations and equity capitalization.
Another Form 8-K explains that the Board of Directors initiated a comprehensive strategic review after receiving multiple unsolicited inbound strategic inquiries, forming a special committee of independent directors and engaging Perella Weinberg Partners as financial advisor. Filings also cover shareholder votes on matters such as equity compensation plans, reverse stock split authorization and increases in authorized shares, as well as executive appointments.
On Stock Titan, DarioHealth’s filings are updated as they are posted to EDGAR, and AI-powered summaries can help interpret complex items such as reverse stock split mechanics, preferred stock conversions, credit agreement amendments and unregistered equity offerings. Users can also review insider and equity-related disclosures reported on Forms 4 and other filings where available, gaining a structured view of DarioHealth’s regulatory and capital markets activity over time.
DarioHealth Corp. filed an 8-K dated August 25, 2025 disclosing a Certificate of Amendment to its Certificate of Incorporation to implement a reverse stock split. The filing lists a press release dated August 25, 2025 and confirms submission of an interactive XBRL cover page. The document names the company's registered common stock (par value $0.0001) and the trading symbol DRIO on The Nasdaq Capital Market LLC, and is signed by the Chief Financial Officer, Treasurer and Secretary, Chen Franco-Yehuda.
DarioHealth Corp. reporting persons Nantahala Capital Management, LLC and principals Wilmot B. Harkey and Daniel Mack disclose beneficial ownership of 4,690,019 shares, representing 9.99% of the outstanding common stock as of June 30, 2025. The disclosed position includes 2,997,716 shares that may be acquired within 60 days through the exercise of warrants, and all voting and dispositive power is reported as shared rather than sole. Nantahala identifies two advised funds with rights to receive proceeds or dividends from more than 5% of the shares reported.
DarioHealth Corp. reported total revenues of $5.369 million for the quarter ended June 30, 2025, split between Services $3.661M and Consumer hardware $1.708M. Gross profit was $2.964M for the quarter and $6.846M for the six months, while operating expenses were $12.164M for the quarter, producing an operating loss of $9.200M. The company recorded a net loss of $12.990M for the quarter and $22.217M for the six months; basic and diluted loss per share was $0.18 for the quarter and $0.33 for six months.
On the balance sheet, cash and cash equivalents were $21.954M (down from $27.764M at year-end), total assets were $108.325M, and accumulated deficit totaled $422.971M. The company refinanced with a $32.5M Callodine credit agreement on April 30, 2025, but did not meet one covenant as of June 30, 2025; Callodine waived the default conditional on a successful equity cure by November 15, 2025. Management discloses that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from issuance.